Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of November 30, 2024. The company has 47,426,851 shares outstanding, with 49,202,229 theoretical voting rights and 49,180,111 exercisable voting rights. Nanobiotix, founded in 2003 and headquartered in Paris, is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix (NBTX) ha riportato il suo ultimo stato dei diritti di voto e del capitale azionario al 30 novembre 2024. L'azienda ha 47.426.851 azioni in circolazione, con 49.202.229 diritti di voto teorici e 49.180.111 diritti di voto esercitabili. Nanobiotix, fondata nel 2003 e con sede a Parigi, è una compagnia di biotecnologie cliniche in fase avanzata quotata sia su Euronext Parigi che sul Nasdaq Global Select Market. L'azienda possiede oltre 25 famiglie di brevetti suddivise in tre piattaforme di nanotech focalizzate su oncologia, biodisponibilità e biodistribuzione, e disturbi del sistema nervoso centrale.
Nanobiotix (NBTX) ha reportado su último estado de derechos de voto y capital social al 30 de noviembre de 2024. La empresa tiene 47.426.851 acciones en circulación, con 49.202.229 derechos de voto teóricos y 49.180.111 derechos de voto ejercitables. Nanobiotix, fundada en 2003 y con sede en París, es una compañía de biotecnología clínica en etapa avanzada que cotiza tanto en Euronext París como en el Nasdaq Global Select Market. La compañía posee más de 25 familias de patentes a través de tres plataformas de nanotecnología centradas en oncología, biodisponibilidad y biodistribución, y trastornos del sistema nervioso central.
Nanobiotix (NBTX)는 2024년 11월 30일 현재의 투표권 및 자본금 상태를 보고했습니다. 회사는 47,426,851주가 발행된 상태이며, 49,202,229개의 이론적 투표권과 49,180,111개의 행사 가능한 투표권을 보유하고 있습니다. 2003년에 설립되어 파리에 본사를 둔 Nanobiotix는 Euronext Paris와 Nasdaq Global Select Market에 모두 상장된 임상 생명공학 회사입니다. 이 회사는 종양학, 생체 이용률 및 생체 분포, 중추 신경계 장애에 중점을 둔 세 가지 나노기술 플랫폼을 통해 25개 이상의 특허 가족을 보유하고 있습니다.
Nanobiotix (NBTX) a fait rapport de sa dernière situation concernant les droits de vote et le capital social au 30 novembre 2024. L'entreprise dispose de 47.426.851 actions en circulation, avec 49.202.229 droits de vote théoriques et 49.180.111 droits de vote pouvant être exercés. Nanobiotix, fondée en 2003 et ayant son siège à Paris, est une entreprise de biotechnologie clinique en phase avancée cotée à la fois sur Euronext Paris et sur le Nasdaq Global Select Market. L'entreprise possède plus de 25 familles de brevets réparties sur trois plateformes de nanotechnologie axées sur l'oncologie, la biodisponibilité et la biodistribution, ainsi que les troubles du système nerveux central.
Nanobiotix (NBTX) hat seinen neuesten Stand zu Abstimmungsrechten und Aktienkapital zum 30. November 2024 berichtet. Das Unternehmen hat 47.426.851 ausgegebene Aktien, mit 49.202.229 theoretischen Abstimmungsrechten und 49.180.111 ausübbaren Abstimmungsrechten. Nanobiotix, 2003 gegründet und mit Hauptsitz in Paris, ist ein biotechnologisches Unternehmen in der späten klinischen Phase, das sowohl an der Euronext Paris als auch am Nasdaq Global Select Market notiert ist. Das Unternehmen besitzt über 25 Patentfamilien, die auf drei Nanotechnologie-Plattformen fokussiert sind, die sich mit Onkologie, Bioverfügbarkeit und Biodistribution sowie Erkrankungen des zentralen Nervensystems beschäftigen.
- Owns portfolio of over 25 patent families across three nanotechnology platforms
- Dual-listed on major exchanges (Euronext Paris and Nasdaq)
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE) --
Paris, France, December 11, 2024
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| November 30, 2024 | 47,426,851 | 49,202,229 | 49,180,111 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
| Media Relations | |
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com |
________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
FAQ
How many shares does Nanobiotix (NBTX) have outstanding as of November 30, 2024?
What is the total number of theoretical voting rights for NBTX as of November 2024?
How many exercisable voting rights does Nanobiotix have as of November 2024?
How many patent families does Nanobiotix currently own?
What are the main technology platforms of Nanobiotix (NBTX)?
